The Cooper Companies, Inc. (NASDAQ:COO) Shares Bought by Pacer Advisors Inc.

Pacer Advisors Inc. raised its position in The Cooper Companies, Inc. (NASDAQ:COO) by 28.5% during the 2nd quarter, Holdings Channel reports. The firm owned 17,465 shares of the medical device company’s stock after acquiring an additional 3,870 shares during the quarter. Pacer Advisors Inc.’s holdings in Cooper Companies were worth $1,525,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its holdings in Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 174 shares during the last quarter. Brown Brothers Harriman & Co. grew its holdings in Cooper Companies by 412.2% in the fourth quarter. Brown Brothers Harriman & Co. now owns 251 shares of the medical device company’s stock valued at $95,000 after purchasing an additional 202 shares during the last quarter. Covestor Ltd grew its holdings in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares during the last quarter. Innealta Capital LLC acquired a new stake in Cooper Companies in the second quarter valued at $25,000. Finally, Crewe Advisors LLC grew its holdings in Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 252 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analysts Set New Price Targets

COO has been the topic of a number of analyst reports. Piper Sandler increased their price objective on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Wells Fargo & Company increased their price objective on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Morgan Stanley increased their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a research note on Tuesday, September 10th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and increased their price objective for the company from $107.00 to $115.00 in a research note on Tuesday, July 16th. Finally, Robert W. Baird increased their price objective on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Stock Performance

NASDAQ COO opened at $109.54 on Friday. The business’s 50-day moving average price is $99.46 and its 200 day moving average price is $95.75. The Cooper Companies, Inc. has a twelve month low of $75.93 and a twelve month high of $112.38. The company has a market capitalization of $21.82 billion, a PE ratio of 64.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.98. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same period in the prior year, the business posted $0.84 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, research analysts predict that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Insider Transactions at Cooper Companies

In other news, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the transaction, the chief operating officer now directly owns 44,696 shares in the company, valued at approximately $4,714,534.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares in the company, valued at approximately $520,488.54. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares in the company, valued at $4,714,534.08. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock worth $27,637,427 in the last three months. 2.00% of the stock is currently owned by company insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.